BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24300852)

  • 21. CD33 BiTE
    Marcinek A; Brauchle B; Rohrbacher L; Hänel G; Philipp N; Märkl F; Strzalkowski T; Lacher SM; Udiljak D; Spiekermann K; Theurich S; Kobold S; Kischel R; James JR; Bücklein VL; Subklewe M
    Cancer Immunol Immunother; 2023 Jul; 72(7):2499-2512. PubMed ID: 37041225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia.
    Musuraca G; De Matteis S; Napolitano R; Papayannidis C; Guadagnuolo V; Fabbri F; Cangini D; Ceccolini M; Giannini MB; Lucchesi A; Ronconi S; Mariotti P; Savini P; Tani M; Fattori PP; Guidoboni M; Martinelli G; Zoli W; Amadori D; Carloni S
    J Transl Med; 2015 Jul; 13():229. PubMed ID: 26174551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
    Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
    Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
    Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
    Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC; Stein A
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
    Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
    Laszlo GS; Estey EH; Walter RB
    Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
    Walter RB
    Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
    Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
    Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
    Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
    van Loo PF; Hangalapura BN; Thordardottir S; Gibbins JD; Veninga H; Hendriks LJA; Kramer A; Roovers RC; Leenders M; de Kruif J; Doornbos RP; Sirulnik A; Throsby M; Logtenberg T; Dolstra H; Bakker ABH
    Expert Opin Biol Ther; 2019 Jul; 19(7):721-733. PubMed ID: 31286786
    [No Abstract]   [Full Text] [Related]  

  • 35. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
    Hoseini SS; Guo H; Wu Z; Hatano MN; Cheung NV
    Blood Adv; 2018 Jun; 2(11):1250-1258. PubMed ID: 29858209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.
    Lu H; Zhou Q; Deshmukh V; Phull H; Ma J; Tardif V; Naik RR; Bouvard C; Zhang Y; Choi S; Lawson BR; Zhu S; Kim CH; Schultz PG
    Angew Chem Int Ed Engl; 2014 Sep; 53(37):9841-5. PubMed ID: 25056598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.
    Kubicka E; Lum LG; Huang M; Thakur A
    Front Immunol; 2022; 13():899468. PubMed ID: 36389764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting CD33 for acute myeloid leukemia therapy.
    Liu J; Tong J; Yang H
    BMC Cancer; 2022 Jan; 22(1):24. PubMed ID: 34980040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
    Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.